Physician profile
Jay D Horton
NPI 1104866458
$326,376.56
in general payments reported to CMS, 2019-2025
6 companies · $15K in 2025
The $15K reported for 2025 was more than what 94% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $66K · 2020: $34K · 2021: $60K · 2022: $61K · 2023: $65K · 2024: $27K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $87K · Travel and Lodging: $17K · Food and Beverage: $1,562.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $87,450.00 |
| Travel and Lodging | $17,030.63 |
| Food and Beverage | $1,562.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $255,073.49 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $44,980.10 | 2019-2024 | |
| Abbvie INC. | $16,081.76 | 2024-2025 | |
| Gilead Sciences, INC. | $6,701.21 | 2019 | |
| Regeneron Pharmaceuticals, INC. | $1,965.00 | 2021-2023 | |
| Eli Lilly and Company | $1,575.00 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Horton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.